PHK
ZVRA icon

Point72 Hong Kong’s Zevra Therapeutics ZVRA Stock Holding History

Point72 Hong Kong’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-334
Closed -$3K – 2404
2021
Q4 		$3K Buy
+334
New +$2.98K ﹤0.01% 1766
2021
Q3 		– Sell
-1,588
Closed -$20K – 2511
2021
Q2 		$20K Buy
+1,588
New +$17.1K ﹤0.01% 1649

Other funds holding ZVRA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Janney Montgomery Scott
Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
RPCONE
Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Point72 Hong Kong's ZVRA Position: Q1 2022 in Review

Point72 Hong Kong sold out of Zevra Therapeutics (ZVRA) in Q1 2022, closing a stake of 334 shares — an estimated $3K sold.

Point72 Hong Kong first reported a position in ZVRA in Q2 2021 and held it in 2 quarters. The position peaked at $20K in Q2 2021. 83 funds tracked by Wall St. Rank hold ZVRA as of Q1 2022.

  • Point72 Hong Kong reported no remaining Zevra Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 334 Zevra Therapeutics shares in Q1 2022, an estimated $3K.
  • Point72 Hong Kong first reported a position in Zevra Therapeutics in Q2 2021 and held it in 2 quarters.
  • Point72 Hong Kong's Zevra Therapeutics position peaked at $20K in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.